Semaglutide oral tablets: what the evidence says

What the OASIS 4 trial actually found

The approval rested primarily on the OASIS 4 phase-3 trial: 307 adults living with obesity or overweight alongside at least one weight-related condition, without type 2 diabetes, followed for 64 weeks. Those taking the oral tablet alongside lifestyle changes lost an average of 13.6% of their body weight. The placebo group lost around 2.4%. Among participants who stayed fully adherent throughout the study, average weight loss reached approximately 16.6%, often rounded to 17% in summaries.

That distinction matters, and it's worth pausing on it. A common assumption is that the headline 17% figure represents what most people taking the tablet will experience. It doesn't; it reflects those who took every dose as directed for the full study duration. The 13.6% average is the more representative number across the whole trial population, and it still represents clinically meaningful weight reduction. Prescribers at our clinical team are well-placed to put both figures in context for your individual circumstances.

The most commonly reported side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea, vomiting and constipation appeared in around 74% of the active group compared with 42% on placebo. Most were mild to moderate and tended to settle as the body adjusted. The MHRA's ongoing pharmacovigilance programme continues to review post-marketing safety data for the broader semaglutide class.

How the tablet differs from the injectable form

Both the tablet and the weekly injection deliver the same active molecule (semaglutide) but the way the body absorbs them is quite different. The tablet uses an absorption enhancer called SNAC to carry semaglutide across the stomach lining intact. Because of that mechanism, how you take it matters more than with an injection: first thing in the morning, on a completely empty stomach, swallowed whole with a small amount of plain water (up to around 120 ml). You then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. Coffee counts as drinking something else, so the kettle can wait.

The practical upside is storage. The tablets sit at room temperature, no cold chain required, which removes one of the logistical pressures that some patients find awkward with injectable treatments. For people who travel frequently or simply dislike the idea of injections, that difference is meaningful, and you can read more about how semaglutide in oral form compares with the injection on our Wegovy oral tablets overview.

The maintenance dose is 25 mg once daily, reached by stepping through 1.5 mg, 4 mg and 9 mg in sequence, spending at least one month at each level. Patients already established on the 2.4 mg weekly injection may move directly to the 25 mg tablet, but only after clinical assessment, the prescriber makes that call, not the patient.

Who the tablets are licensed for in the UK

The MHRA licence covers adults with a BMI of 30 or above, or those with a BMI between 27 and 29.9 who have at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Treatment is taken alongside a reduced-calorie diet and increased physical activity, the tablet works within a broader plan, not instead of one. UK guidance also notes that lower BMI thresholds apply for some ethnic backgrounds, which a prescriber will factor into their assessment.

The tablets are not licensed for use during pregnancy, breastfeeding or when trying to conceive, and they are not indicated for under-18s. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome will not be suitable. As with any prescription medicine, the full contraindication list sits in the patient information leaflet, and NHS guidance on semaglutide sets out the key clinical considerations in plain language.

It is also worth being clear about what the tablets are not. Rybelsus is an oral semaglutide tablet, but it is licensed for type 2 diabetes at different doses (3 mg, 7 mg and 14 mg) and is a separate product from the Wegovy weight-loss tablet. If you have seen references to semaglutide oral pills for diabetes, that is Rybelsus, a different prescription, different doses, different clinical pathway. Our semaglutide tablets guide covers this distinction in more detail.

Getting access: NHS position and the private route

The Wegovy tablet is not yet available on the NHS. A NICE appraisal would be needed before NHS commissioning could begin, and that process takes time. For now, access is via private prescription only. The cost of the Wegovy tablet on a private basis reflects prescription, clinical assessment and any associated support, the same considerations that apply to the injectable form.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber. There is no algorithm making clinical decisions. If you order before 12pm Monday to Friday and are approved as clinically suitable, treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. Our pharmacy is registered with the GPhC (registration number 9012878, verifiable at the GPhC register). If you would like to explore whether oral semaglutide tablets are appropriate for you, start your free consultation and a prescriber will review your details the same day.